Recent developments to share with you

Quality is the lifeline of an enterprise – its core and soul.

2025-01-26


Quality is the lifeline of an enterprise – its core and soul. To further standardize our R&D processes, effectively manage risks, and establish standardized operations and management practices, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. passed the ISO 9001 Quality Management System (CNAS) certification in January 2025.

Achieving ISO 9001 (CNAS) certification demonstrates our company's capabilities and serves as an incentive for future growth. We will continue to optimize and standardize our management systems, improve the effectiveness of our quality management system, enhance our management level, and drive the rapid development of the company.

 

Keywords:

Related information

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03

Good News | Kangchuanji Pharmaceutical’s Sildenafil Citrate Orally Disintegrating Tablets Have Been Approved for Market Launch

According to the drug approval document delivery information released by the NMPA, sildenafil citrate orally disintegrating tablets manufactured by Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. have been approved for marketing as a Class 4 generic drug under the new chemical drug registration classification, and are deemed to have passed the consistency evaluation.

2026-06-29

A Strong Start to the New Year – Kangchuanji Achieves Multiple Approvals

The new year begins with a wave of good news. Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. has made an excellent start, backed by professional expertise. According to NMPA drug approval information, the following products have been approved for marketing or have passed consistency evaluation: Famotidine Injection (2ml:20mg), Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (2.5/1000mg and 5/1000mg), Isosorbide Dinitrate Tablets (5mg), Vitamin B6 Injection (100mg/ml), Cefdinir Granules (50mg/0.5g), and Ambroxol and Clenbuterol Oral Solution (1ml: ambroxol hydrochloride 1.5mg and clenbuterol hydrochloride 1μg). Among these, Isosorbide Dinitrate Tablets are the first in China to pass consistency evaluation. As a partner, Kangchuanji provided solid pharmaceutical R&D services, successfully supporting these drugs through the review and approval process.

2026-03-23